FINWIRES · TerminalLIVE
FINWIRES

$MGNX

2 stories mentioning MGNXUpdated 80d ago

Every FINWIRES story that references MGNX, newest first.

What are analysts saying about MGNX?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on MGNX?

Wire

MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals

MacroGenics (MGNX) closed the sale of its good manufacturing practices drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million, the companies said Thursday.The transaction includes MacroGenics' manufacturing site and warehouse in Maryland, with Bora also absorbing 140 employees, according to a statement.Concurrently, the companies said they signed a supply agreement, under which Bora will support process development and drug substance production for MacroGenics' pipeline requirements.MacroGenics shares rose more than 3% in Thursday trading.Price: $4.78, Change: $+0.16, Percent Change: +3.35%

$MGNX
Research

B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3

MacroGenics (MGNX) has an average rating of hold and mean price target of $4, according to analysts polled by FactSet.

$MGNX

Track with the FINWIRES app suite

FolioX
FolioX
Track MGNX in your portfolio
WheelAI
WheelAI
Analyze MGNX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on MGNX